| IN 426/2026 | IN 426/2026 — UDI database transmission and management Complete ANVISA Legis native HTML expression, including every operative paragraph and native table row/cell/span in source order. The served page declares UTF-8 but appends a Latin1-encoded nonoperative editorial disclaimer; its three replacement characters are preserved as publisher artifacts, not silently repaired. Operative legal text is intact. The controlling publication is the federal DOU; scope and later currentness require separate verification. | Registration | March 1, 2026 | Official↗ |
| RDC 925/2024 | Personalized Medical Devices Requirements for manufacture, commercialization, import, and use of personalized medical devices, including patient-matched and custom-made devices. | Registration | September 24, 2024 | Official↗ |
| RDC 903/2024 | RDC 903/2024 — transfers and company-data changes Complete eight-page official Espírito Santo health-secretariat hosted expression of ANVISA RDC 903/2024. It addresses corporate/commercial operations with unchanged technical-sanitary conditions; Article3 excludes unrelated corporate-name changes. The federal DOU publication controls. This source does not establish one route for every device/IVD change or later currentness. | Registration | September 9, 2024 | Official↗ |
| RDC 848/2024 | Essential Safety and Performance Requirements Essential safety and performance requirements for medical devices and in vitro diagnostic medical devices (IVDs). Replaces the previous essential requirements framework used with RDC 751/2022. | Registration | September 4, 2024 | Official↗ |
| RDC 884/2024 | UDI Implementation Timeline Extension Amends RDC 591/2021, extending UDI implementation deadlines. Rectified in the Official Gazette on July 2, 2024. | UDI | July 1, 2024 | Official↗ |
| IN 290/2024 | Leveraging Foreign Regulatory Authorizations (AREE) Establishes an optimized analysis procedure for Class III/IV marketing authorization petitions by using assessments from Equivalent Foreign Regulatory Authorities (AREE/EFRA), including FDA, Health Canada, Japan, and Australia TGA. | Registration | June 3, 2024 | Official↗ |
| RDC 857/2024 | RDC 857/2024 — sanitary-surveillance fee collection procedures Complete ANVISA Legis native HTML expression, including every operative paragraph and native table row/cell/span in source order. The served page declares UTF-8 but appends a Latin1-encoded nonoperative editorial disclaimer; its three replacement characters are preserved as publisher artifacts, not silently repaired. Operative legal text is intact. The controlling publication is the federal DOU; scope and later currentness require separate verification. Source explicitly identifies DOU publication May8,2024 and corrected republication May9,2024; selected expression retains the republication note. | Registration | June 3, 2024 | Official↗ |
| RDC 830/2023 | In Vitro Diagnostic (IVD) Medical Devices Regulation for IVD medical devices including classification (Class I-IV), registration pathways, self-testing requirements, and companion diagnostics. Replaced RDC 36/2015. | Registration | June 1, 2024 | Official↗ |
| RDC 850/2024 | GMP Certificate Extension for MDSAP Manufacturers Amends Article 8 of RDC 497/2021 so qualifying Good Manufacturing Practices certificates granted through MDSAP are valid for four years, subject to continued participation in MDSAP. | GMP/QMS | April 1, 2024 | Official↗ |
| RDC 837/2023 | Clinical Investigations with Medical Devices Procedures and Good Clinical Practice requirements for clinical investigations with medical devices in Brazil whose results may support Class III and IV registration. | Clinical Trials | December 15, 2023 | Official↗ |
| RDC 751/2022 | Medical Device Registration and Classification Core regulation for medical device classification (Class I-IV) and registration pathways (notification vs. marketing authorization) in Brazil. | Classification | March 1, 2023 | Official↗ |
| RDC 777/2023 | RDC 777/2023 — amendment to RDC 751/2022 Complete two-page official Espírito Santo health-secretariat hosted expression of ANVISA RDC 777/2023, amending the medical-device RDC 751/2022. The Annex II grid and publisher disclaimer are retained. The federal DOU publication controls; this MD amendment does not establish IVD rules or later currentness. | Registration | March 1, 2023 | Official↗ |
| RDC 743/2022 | RDC 743/2022 — risk classifications and decision-period annexes Complete ANVISA Legis native HTML expression, including every operative paragraph and native table row/cell/span in source order. The served page declares UTF-8 but appends a Latin1-encoded nonoperative editorial disclaimer; its three replacement characters are preserved as publisher artifacts, not silently repaired. Operative legal text is intact. The controlling publication is the federal DOU; scope and later currentness require separate verification. | Registration | September 1, 2022 | Official↗ |
| RDC 657/2022 | Software as Medical Device (SaMD) Requirements for regularizing Software as a Medical Device (SaMD), including classification, technical documentation, software validation, cybersecurity, labeling, and post-market responsibilities. | Software/SaMD | July 1, 2022 | Official↗ |
| RDC 687/2022 | GMP Inspection and Certification Programs for Medical Devices Inspection programs and criteria for granting or renewing Good Manufacturing Practices certificates for medical device manufacturers, including use of MDSAP audit reports and regulatory-authority inspection information. | GMP/QMS | June 1, 2022 | Official↗ |
| RDC 665/2022 | Good Manufacturing Practice (GMP) for Medical Devices GMP requirements for medical device manufacturers including quality management system, design controls, and production processes. Replaced RDC 16/2013. | GMP/QMS | May 2, 2022 | Official↗ |
| RDC 591/2021 | Unique Device Identification (UDI) System Brazil's UDI system requiring unique identifiers, machine-readable and human-readable labeling, and submission to ANVISA's UDI database. Implementation deadlines were later amended by RDC 884/2024. | UDI | January 10, 2022 | Official↗ |
| RDC 551/2021 | Field Safety Corrective Actions Notification Requires registration holders to execute and notify field safety corrective actions, including recalls, corrections, and safety communications to ANVISA and healthcare facilities. | Vigilance | October 1, 2021 | Official↗ |
| RDC 497/2021 | GMP and Distribution/Storage Certification Procedures Administrative procedures for granting Good Manufacturing Practices certificates and Good Distribution and/or Storage Practices certificates. Article 8 amended by RDC 850/2024 to extend MDSAP-linked certificates from 2 to 4 years. | GMP/QMS | June 1, 2021 | Official↗ |
| IN 74/2020 | Instrução Normativa No. 74/2020 — change-control annexes Complete ANVISA Legis native HTML expression of IN 74/2020, including both change-control annexes for scoped medical-device and IVD subjects. The publisher states that its text does not replace the official Gazette publication. Later amendments/currentness and subject-specific applicability require separate verification. | Registration | September 18, 2020 | Official↗ |
| RDC 40/2015 | Notification Process for Class I and II Medical Devices Simplified notification process for Class I and II medical devices. Revoked by RDC 751/2022. | Registration | October 26, 2015 | Official↗ |
| RDC 67/2009 | Technovigilance Rules for Medical Devices Establishes technovigilance rules for medical device registration holders in Brazil. Defines adverse event reporting requirements, timelines, and post-market surveillance procedures. | Vigilance | December 23, 2009 | Official↗ |
| ANVISA — notified-device alteration FAQ | Alteração de notificação Complete captured official ANVISA seven-question FAQ on notified-device alterations, including every answer, original list, warning and source link. The complete captured answers are presented together for reading. The portal records 2020 publication and March2023 modification; these are page metadata rather than legal effective dates. Historical source guidance and its statements about combined changes are preserved without certifying current law or merging the distinct registration and notification routes. Source-only; no fact, fee, timeline, binding or question-status promotion. | Registration | — | Official↗ |
| ANVISA — registered-device alteration FAQ | Alteração pós-registro Complete captured official ANVISA seven-question FAQ on postregistration alterations, including every answer, original list, warning and source link. The complete captured answers are presented together for reading. The portal records 2020 publication and March2023 modification; these are page metadata rather than legal effective dates. Historical source guidance and its statements about combined changes are preserved without certifying current law or merging the distinct registration and notification routes. Source-only; no fact, fee, timeline, binding or question-status promotion. | Registration | — | Official↗ |
| Decreto nº 10.178, de 18 de dezembro de 2019 | Decree No. 10.178/2019 — complete Chamber consolidated text Complete official Chamber consolidated HTML of the general economic-activity risk-classification and administrative-decision framework: Articles 1–21 with inserted Article 18-A, all publisher amendment annotations, source article anchors, legal links, crest and signatures. This is not a medical-device or IVD-specific instrument. Any application to ANVISA procedures requires the specific companion authority and its exceptions; the text does not establish a universal 60-day or 90-day device alteration period. The historical capture is preserved without a currentness or blanket legal-effect determination. | General | — | Official↗ |